Gyre Therapeutics (GYRE) Expected to Announce Earnings on Thursday

Gyre Therapeutics (NASDAQ:GYRE) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Gyre Therapeutics to post earnings of ($0.06) per share and revenue of $31.6070 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.The company had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million. On average, analysts expect Gyre Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Gyre Therapeutics Stock Down 1.8%

Shares of GYRE stock opened at $7.78 on Wednesday. The firm has a fifty day moving average of $7.61 and a 200-day moving average of $7.71. Gyre Therapeutics has a 12-month low of $6.57 and a 12-month high of $11.78. The company has a market capitalization of $754.58 million, a price-to-earnings ratio of 778.78 and a beta of 2.03.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after purchasing an additional 1,900 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after purchasing an additional 5,135 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GYRE. Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Gyre Therapeutics currently has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.